0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Cutting Edge |

Nicotine for Pyoderma Gangrenosum FREE

Ronni Wolf, MD; Vincenzo Ruocco, MD
[+] Author Affiliations

Section Editor: George J. Hruza, MD
Assistant Section Editor: Lynn A. Cornelius, MD
Assistant Section Editor: John Starr, MD

More Author Information
Arch Dermatol. 1998;134(9):1071-1072. doi:10.1001/archderm.134.9.1071.
Text Size: A A A
Published online

REPORT OF A CASE

A 35-year-old man with no past medical illness developed bloody diarrhea with up to 12 loose stools per day and abdominal pain in February 1984. He had smoked 1 pack of cigarettes per day for 16 years until he stopped smoking 2 months prior to the onset of his illness. In March 1984, he was hospitalized because of toxic dilatation of the colon (toxic megacolon). Treatment consisted of intravenous fluids and electrolytes, broad-spectrum antibiotics, and corticosteroids. After the condition had slowly improved, he was released on a daily dosage of 40 mg of prednisone, 4 g of sulfasalazine, and 800 mg of cimetidine. Findings of colonoscopic and sigmoidoscopic examinations with biopsies were inconclusive, and he was diagnosed as having active nongranulomatous colitis similar to inflammatory bowel disease, without being able to differentiate between ulcerative colitis and Crohn disease. He subsequently had short remissions with only minimal activity and many relapses with severe symptoms. He was treated with 1.5 to 3 g/d of sulfasalazine, and 50 to 100 mg/d of azathioprine, as well as intermittent courses of prednisone. Cimetidine, iron, and vitamins were also administered.

We first saw the patient in July 1985 for 2 multiloculated necrotic ulcers on both legs surrounded by a raised, thickened, undermined bluish edge. The diagnosis of pyoderma gangrenosum was made clinically. Therapy with 60 mg/d of prednisone was started and gradually reduced to 25 mg/d of prednisone over 1 year, after which the ulcers healed. In July 1992, he again developed pyoderma gangrenosum on 1 leg and underwent a similar treatment and course over nearly 1 year until the ulcer had completely healed.

In August 1995, there was an exacerbation of his bowel symptoms together with pyoderma gangrenosum on his left leg. Therapy consisted of blood transfusions and 30 mg/d of prednisone, in addition to the sulfasalazine and azathioprine regimens. His bowel symptoms but not his cutaneous lesions improved gradually, and prednisone was slowly tapered within 5 months to 12.5 mg/d. In March 1996, azathioprine was stopped on his request. However, the pyoderma gangrenosum did not respond to this treatment; rather, the cutaneous situation in August 1996 was about the same as it had been 1 year earlier.

THERAPEUTIC CHALLENGE

Currently available treatment for pyoderma gangrenosum is far from satisfactory. Only 2 major drugs, corticosteroids and cyclosporine, have proved effective in the treatment of pyoderma gangrenosum. Unfortunately, they may be poorly tolerated and are associated with significant adverse effects. While the intestinal symptoms of our patient responded favorably to systemic corticosteroid therapy, his cutaneous symptoms responded only very slowly for the first 2 attacks and not at all for his last one.

Our challenge was to devise an alternative safe and effective treatment.

SOLUTION

Therapy with topical nicotine was started.

The patient was instructed to apply a 10-mg nicotine patch directly on the ulcer and replace it every 24 hours. Systemic treatment was continued, except that the prednisone dosage was lowered to 10 mg/d.

There was a dramatic improvement of the cutaneous lesions with this regimen. The ulcer became smaller and less inflamed within 2 weeks and cleared up completely within 4 weeks, leaving only postinflammatory hyperpigmented scars.

Treatment with nicotine patches was discontinued 1 month later. Within 2 weeks, the same symptoms recurred, with an exacerbation of the bowel symptoms together with pyoderma gangrenosum on his left leg. He was treated with 60 mg/d of prednisone, in addition to sulfasalazine and 100 mg/d of azathioprine. With this treatment, the bowel symptoms improved rapidly and prednisone was tapered within 2 months to 10 mg/d. We saw the patient 2 weeks later (the prednisone dosage was then 30 mg/d); there was a large, oozing, inflamed ulcer on his left leg. Treatment with nicotine patches was reintroduced, and the ulcer healed again within 3 months.

We did not observe any adverse effects during therapy with the nicotine patches.

COMMENT

Ulcerative colitis is largely a disease of nonsmokers. Ex-smokers often acquire the disease within a few years of stopping the habit.1 Patients who smoke intermittently often experience improvement of their symptoms during periods of smoking. Based on these observations, several trials have been conducted in an attempt to treat patients with nicotine in various forms. In most of the open studies, smoking, nicotine chewing gum, or nicotine patches appeared to improve symptoms of this inflammatory bowel disease.2 This result has also been confirmed in a recent double-blind, controlled trial with transdermal nicotine patches.3

Pyoderma gangrenosum is well known to be associated with ulcerative colitis.4 It responds to similar treatment modalities, such as systemic corticosteroid and immunosuppressive drug therapy. Therefore, it is logical to assume that pyoderma gangrenosum would benefit from nicotine therapy, as has been shown for ulcerative colitis. There are only a few reports of such treatment for this dermatosis.5,6 The reason for this might be the rarity of the disease, estimated at 3 cases per 1 million population per year.2 However, we believe that lack of awareness of this form of therapy among dermatologists is the main reason for the scarcity of studies on this therapeutic modality.

Herein we describe a patient with pyoderma gangrenosum who responded twice to topical nicotine within 4 weeks and 3 months, respectively, without any adverse effects. It is noteworthy that his bowel disease appeared for the first time 2 months after he stopped smoking. Furthermore, his pyoderma gangrenosum and bowel symptoms appeared shortly after withdrawal of treatment with nicotine patches.

Transdermal nicotine patches may be associated with local cutaneous and systemic adverse effects.7 The most frequently reported events have been central nervous system effects (headache, dizziness, and fatigue), sleep disturbances (insomnia and nightmares), cardiovascular effects (increased blood pressure, heart rate, and peripheral vasoconstriction), and gastric disturbances (constipation, flatulence, nausea, vomiting, dyspepsia, and taste perversion). There have also been reports of sweating, muscle and limb pain, paresthesia, increased cough, and palpitations. Because of the pharmacokinetic profile of transdermal delivery systems (slow rate of absorption of nicotine and low, stable plasma nicotine concentrations), systemic adverse events are usually mild and do not often lead to discontinuation of therapy.

However, with the use of nicotine patches on multiple open lesions, the possibility of reaching higher and even toxic plasma nicotine concentrations should be seriously considered and symptoms of nicotine overdose carefully monitored.

Undoubtedly, large randomized clinical trials are more significant than case reports on encouraging therapeutic results in individual patients. However, before conclusive data can be provided, we believe that early sporadic reports are effective for dissemination of the information and are often followed by a plethora of such communications. Finally, it may be that efficacy will be noted only in those patients with a similar history, ie, inflammatory bowel disease onset following cessation of smoking.

ARTICLE INFORMATION

Presented in part at the Ninth Zagazig International Conference of Dermatology and Venereology, Cairo, Egypt, December 7, 1996.

REFERENCES

Calkins  BM A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;341841- 1845
Link to Article
Srivastava  EDRussel  MAHFeyerabend  CWilliams  GTMasterson  JGRhodes  J Transdermal nicotine in active colitis. Eur J Gastroenterol Hepatol. 1991;3815- 818
Pullan  RDRhodes  JGanesh  S  et al.  Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330811- 815
Link to Article
Powell  FCSu  DPerry  HO Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34395- 409
Link to Article
Kanekura  TUsuki  KKanzaki  T Nicotine for pyoderma gangrenosum [letter]. Lancet. 1995;3451058
Link to Article
Kanekura  TKanzaki  T Successful treatment of pyoderma gangrenosum with nicotine chewing gum [letter]. J Dermatol. 1995;227704- 7705
Palmer  KJBuckley  MMFaulds  D Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992;44498- 529
Link to Article

Figures

Tables

References

Calkins  BM A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;341841- 1845
Link to Article
Srivastava  EDRussel  MAHFeyerabend  CWilliams  GTMasterson  JGRhodes  J Transdermal nicotine in active colitis. Eur J Gastroenterol Hepatol. 1991;3815- 818
Pullan  RDRhodes  JGanesh  S  et al.  Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330811- 815
Link to Article
Powell  FCSu  DPerry  HO Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34395- 409
Link to Article
Kanekura  TUsuki  KKanzaki  T Nicotine for pyoderma gangrenosum [letter]. Lancet. 1995;3451058
Link to Article
Kanekura  TKanzaki  T Successful treatment of pyoderma gangrenosum with nicotine chewing gum [letter]. J Dermatol. 1995;227704- 7705
Palmer  KJBuckley  MMFaulds  D Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992;44498- 529
Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

932 Views
18 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Smoking can be good for you. J Cosmet Dermatol 2004;3(2):107-11.
Jobs